Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 19Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 14Neoplasms 11Lung Neoplasms 11Neoplasm Metastasis 7Breast Neoplasms 6Brain Neoplasms 6Head and Neck Neoplasms 4Gliosarcoma 4Glioblastoma 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Prostatic Neoplasms 2Oligodendroglioma 2Non-Squamous Non-Small Cell Lung Cancer 2Glioma 2Familial ependymoma 2Esophageal Neoplasms 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2Urinary Bladder Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1

Interventions

Erlotinib Hydrochloride 2RG-1507 monoclonal antibody 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Non-Squamous Non-Small Cell Lung Cancer × Erlotinib Hydrochloride × Clear all
NCT00760929 2021-01-05

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Hoffmann-La Roche

Phase 2 Terminated
171 enrolled 17 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01990261 2016-09-16

STAR

Hoffmann-La Roche

Terminated
33 enrolled 12 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡